Kangai Medical Secures Tens of Millions in Series A+ Funding to Accelerate Clinical Oncology Supportive Care Solutions

VCBeat has learned at the earliest opportunity that a provider of clinical oncology supportive care solutions—Beijing AiNST Medical Technology Co., Ltd. (hereinafter referred to as “AiNST”)Announces Completion of Funding Round Led byMARATHON VENTURE PARTNERSLed the tens of millions of yuan in Series A+ financing.

AiNST is committed to the mission of “Innovative Comprehensive Assessment, Precise Supportive Care.” Starting with in-hospital oncology nutrition, it provides an integrated solution for oncology nutrition diagnosis and treatment that combines “devices + software + nutritional products,” aiming to become a leader in cancer supportive care and whole-course management in China.

AiNST’s integrated solution for oncology nutrition screening, assessment, diagnosis, and treatment standardization enables the completion of screening, evaluation, diagnosis, and treatment within three minutes, boosting dietitian efficiency by more than tenfold. By empowering physicians and pharmacists with assisted diagnostic and therapeutic decision-making, it delivers intelligent, personalized nutritional treatment plans for patients:

In 2015, the company partnered with Dana-Farber Cancer Institute at Harvard University to develop an automated, intelligent, and digital oncology supportive care solution tailored to China’s specific conditions, by leveraging Harvard’s expertise in cancer supportive care and integrating it with local practices.

AiNST has long supported the Oncology Nutrition Professional Committee of the China Anti-Cancer Association, chaired by Professor Shi Hanping. It has established a scientific research database on oncology nutrition and published hundreds of academic achievements. In 2023, it was honored by Healsan Consulting LLC as one of the “Top 5 Most Active Scholars in Global Nutrition in 2022,” ranking second and standing as the only Asian scholar among the top five.

Ying Xitang, the company’s founder and chairman, previously founded Beijing Kemai Diagnostics, which successfully listed on the STAR Market in 2021.

AiNST took the lead in obtaining the registration certificate for clinical nutrition analyzers in 2020. To date, its devices have been installed in nearly 200 hospitals, with a client portfolio that includes the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Tianjin Cancer Hospital, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center, and provincial cancer hospitals in Zhejiang, Jiangsu, and Anhui provinces.

In 2023, the AiNST Project was selected for the National Cancer Center’s “Initiative to Enhance Oncology Nutrition Diagnosis and Treatment Capabilities,” providing structured data collection and statistical analysis for multicenter clinical studies. AiNST’s intelligent oncology nutrition workstations have established out-of-hospital oncology nutrition collaborations with oncology DTP pharmacies such as Sinopharm, Gaoji Pharmacy, and Sipei.

In the future, as China’s aging population and cancer incidence rates continue to rise, coupled with the upgrading of healthcare consumption, AiNST is emerging as a leading enterprise in the niche field of oncology supportive care.

MARATHON VENTURE PARTNERS, established in 2016, is an early-stage venture capital fund focused on the digital health technology sector. Currently, the cumulative assets under management of its multiple RMB and USD funds exceed the equivalent of RMB 3 billion.

MARATHON VENTURE PARTNERS focuses on early-stage investment opportunities in digital health, making forward-looking strategic layouts across three key infrastructures: efficient patient access, innovative payment models, and operational efficiency enhancement. This approach supports the transformation and upgrading of healthcare systems in China and globally, driving cost reduction, efficiency improvement, quality enhancement, and cost containment. To date, MARATHON VENTURE PARTNERS has invested in nearly 100 high-quality innovative enterprises across various digital health sectors.